Pharmacogenomics (PGx) enables personalized treatment for the prediction of drug
response and to avoid adverse drug reactions. Currently, PGx mainly relies on the genetic …

The aim of this study was to establish the physiologically based pharmacokinetic (PBPK)
model of flurbiprofen related to CYP2C9 genetic polymorphism and describe the …

The antiarrhythmic agent quinidine is a potent inhibitor of cytochrome P450 (CYP) 2D6 and
P‐glycoprotein (P‐gp) and is therefore recommended for use in clinical drug–drug …

The cytochrome P450 2D6 (CYP2D6) is a key xenobiotic-metabolizing enzyme involved in
the clearance of many drugs. Genetic polymorphisms in CYP2D6 contribute to the large inter …

Aim: Antimalarial primaquine (PQ) eliminates liver hypnozoites of Plasmodium vivax.
CYP2D6 gene variation contributes to PQ therapeutic failure. Additional gene variation may …

The cytochrome P450 2D6 (CYP2D6) genotype is the single most important determinant of
CYP2D6 activity as well as interindividual and interpopulation variability in CYP2D6 activity …

Paxlovid, a drug combining nirmatrelvir and ritonavir, was designed for the treatment of
COVID-19 and its rapid development has led to emergency use approval by the FDA to …

Clomiphene, a selective estrogen receptor modulator (SERM), has been used for the
treatment of anovulation for more than 50 years. However, since (E)-clomiphene ((E)-Clom) …

In this study, we investigated the effect of Hippophae rhamnoides L.(HRP) on the activity of
CYP2D6 via the CAMP/PKA/NF-κB pathway in rats with Bacille Calmette–Guerin (BCG) …

Pitavastatin, a potent 3-hydroxymethylglutaryl coenzyme A reductase inhibitor, is indicated
for the treatment of hypercholesterolemia and mixed dyslipidemia. Hepatic uptake of …